CN103356531A - Application of Sarcaboside B in medicine used for treating cervical cancer - Google Patents
Application of Sarcaboside B in medicine used for treating cervical cancer Download PDFInfo
- Publication number
- CN103356531A CN103356531A CN 201310262618 CN201310262618A CN103356531A CN 103356531 A CN103356531 A CN 103356531A CN 201310262618 CN201310262618 CN 201310262618 CN 201310262618 A CN201310262618 A CN 201310262618A CN 103356531 A CN103356531 A CN 103356531A
- Authority
- CN
- China
- Prior art keywords
- sarcaboside
- cervical cancer
- application
- medicine
- human cervical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Sarcaboside B in a medicine used for treating cervical cancer and belongs to the technical field of new applications of medicines. In vitro MTT (methyl thiazolyl tetrazolium) antineoplastic activity evaluation shows that Sarcaboside B has an obvious inhibiting effect on growth of human cervical cancer cell strains such as HeLa, HeLa229, HCE1 and CaSKi, so that Sarcaboside B can be used for preparing an anti-cervical-cancer medicine and has a good development application prospect; the application of Sarcaboside B in preparation of the medicine used for treating human cervical cancer is disclosed for the first time, a brand new skeleton type is adopted, and Sarcaboside B has an unexpected inhibitory activity on human cervical cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound S arcaboside B, relate in particular to the application of Sarcaboside B in the preparation medicament for resisting cervical cancer.
Technical background
Cancer is to one of disease of human life's health hazard maximum, and annual have a large amount of people to die from cancer.The research and development of cancer therapy drug are the focuses of study of pharmacy always.Having 74% to be the natural product or derivatives thereof in the antitumor drug, is exactly the present reasonable antitumor drug of effect clinically such as paclitaxel and derivant thereof.Therefore, searching anticancer compound or lead compound have great importance from natural product.
The compound S arcaboside B that the present invention relates to is one and delivered (Li in 2012, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.) New skeleton compound, this chemical compound has brand-new framework types, there is not at present the report about activity, belong to open first for the purposes of the Sarcaboside B that the present invention relates in preparation treatment cervical cancer medicine, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cervical cancer obviously has significant progress.
Summary of the invention
The invention provides the application of compound S arcaboside B in the preparation antitumor drug.
The present invention adopts following technical scheme: the application of Sarcaboside B in the preparation medicament for resisting cervical cancer, and the structural formula of Sarcaboside B is shown in formula I:
Formula I
The present invention finds that by external MTT anti-tumor activity evaluation Sarcaboside B also has significant inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi, suppresses the IC of this 4 strain Growth of Cells
50Value is respectively 1.23 ± 0.06 μ M, 3.15 ± 0.06 μ M, 1.21 ± 0.04 μ M and 1.13 ± 0.04 μ M.Therefore, Sarcaboside B can for the preparation of medicament for resisting cervical cancer, have good development prospect.
The purposes of the Sarcaboside B that the present invention relates in preparation treatment cervical cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for cervical cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other chemical compounds, possess outstanding substantive distinguishing features, the control that is used for simultaneously cervical cancer obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
The specific embodiment
The preparation method of compound S arcaboside B involved in the present invention is referring to document (Li, X. et al., 2012. Two New-Skeleton Compounds from Sarcandra glabra. Helvetica Chimica Acta 95 (6), 998-1002.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subjected to any restriction of specific embodiment, but limited by claim.
Embodiment 1: the preparation of compound S arcaboside B tablet involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant 180 grams of preparation tablet, mixing, conventional tablet machine are made 1000.
Embodiment 2: the preparation of compound S arcaboside B capsule involved in the present invention:
Get 20 and digest compound Sarcaboside B, add conventional adjuvant such as starch 180 grams of preparation capsule, mixing is encapsulatedly made 1000.
Further specify its pharmaceutically active below by pharmacodynamic experiment.
Experimental example: adopt mtt assay assessing compound Sarcaboside B to the growth inhibited effect of human cervical carcinoma cell lines
1. method: the cell that is in the growth logarithmic (log) phase: Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4The concentration kind is in 96 orifice plates.Suck original culture medium after cell culture 24 h are adherent.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium that contain 10% hyclone; It is 100 μ M that the replacing of drug treating group contains concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Sarcaboside B of 0.01 μ M and 0.001 μ M.After cultivating 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2Incubator is cultivated 4 h, then suck 100 μ L supernatants along culture fluid top, add 100 μ L DMSO, 10 min are placed in the dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and according to light absorption value calculating cell survival situation, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
Drug treating/ Δ OD
Blank* 100.
2. result: Sarcaboside B has significant inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi.This chemical compound suppresses the IC of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi growth
50Value is respectively: 1.23 ± 0.06 μ M, 3.15 ± 0.06 μ M, 1.21 ± 0.04 μ M and 1.13 ± 0.04 μ M.
Shown that by above-described embodiment Sarcaboside B of the present invention has good inhibitory action to the growth of Human cervical carcinoma cell line HeLa, HeLa229, HCE1 and CaSKi.Prove that thus Sarcaboside B of the present invention has the anti-cervical cancer activity, can be for the preparation of medicament for resisting cervical cancer.
Claims (1)
1.Sarcaboside the application of B in treatment cervical cancer medicine, described compound S arcaboside B structure as
Formula IShown in:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262618 CN103356531A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating cervical cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310262618 CN103356531A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating cervical cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103356531A true CN103356531A (en) | 2013-10-23 |
Family
ID=49359353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310262618 Pending CN103356531A (en) | 2013-06-27 | 2013-06-27 | Application of Sarcaboside B in medicine used for treating cervical cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103356531A (en) |
-
2013
- 2013-06-27 CN CN 201310262618 patent/CN103356531A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102872148B (en) | Application of Houttuynoid D in medicament for treating tongue cancer | |
| CN103356531A (en) | Application of Sarcaboside B in medicine used for treating cervical cancer | |
| CN103356589A (en) | Application of Sarcaboside A in preparation of drug for treating cervical cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103356550A (en) | Application of Sarcaboside B in medicine used for treating laryngeal cancer | |
| CN103356532A (en) | Application of Sarcaboside B in medicine used for treating breast cancer | |
| CN103356534A (en) | Application of Sarcaboside B in medicine used for treating colorectal cancer | |
| CN103356541A (en) | Application of Sarcaboside B in medicine used for treating gastric cancer | |
| CN103356560A (en) | Application of Sarcaboside B in medicine used for treating prostate cancer | |
| CN103356553A (en) | Application of Sarcaboside A in preparation of drug for treating breast cancer | |
| CN103356538A (en) | Application of Sarcaboside A in preparation of drug for treating ovarian cancer | |
| CN103356559A (en) | Application of Sarcaboside B in preparation of medicines for treating tongue cancer | |
| CN103371996A (en) | Application of Sarcaboside A in medicine for treating nasopharynx cancer | |
| CN103356547A (en) | Application of Sarcaboside A in preparation of drug for treating skin cancer | |
| CN103356577A (en) | Application of Sarcaboside A in preparation of drug for treating stomach cancer | |
| CN103356535A (en) | Application of Sarcaboside A in preparation of drug for treating pancreatic cancer | |
| CN103356561A (en) | Application of Sarcaboside B in medicine used for treating renal cancer | |
| CN103120666A (en) | Application of Aphanamixoid A in medicine for treating human cervical carcinoma | |
| CN103393652A (en) | Application of Sarcaboside A to medicament for treatment of laryngocarcinoma | |
| CN103356585A (en) | Application of Sarcaboside B in preparation of medicines for treating bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131023 |